Sansure Biotech's SARS-CoV-2 Rapid Antigen Test has obtained CE certification

On April 13, the SARS-CoV-2 Rapid Antigen Test (immunochromatography Assay) developed by Sansure Biotech Inc. has obtained CE certification! This means that the test can be sold in EU countries and countries that recognize EU CE certification.

The SARS-CoV-2 Antigen Test is an important method of epidemic prevention and control, and can be used as an auxiliary diagnosis of COVID-19. Sansure Biotech's SARS-CoV-2 Rapid Antigen Test can be simply and fast operated by individuals by collecting their nasal swabs without any testing equipment. The results are available in 15-20 minutes, which is convenient for individuals and families to quickly test SARS-CoV-2

Sansure Biotech's SARS-CoV-2 Rapid Antigen Test obtained the EU CE1434 self-test certificate, indicating that the company's immune detection product performance has been recognized by official institutions. It has further enriched Sansure 's full-scenario SARS-CoV-2 detection solutions, expanded and met the needs of detection and prevention at all levels in the global market.